This coronavirus stock is up over 1,000% since the market crash, but is it still worth buying?

Jabran Khan explores whether this coronavirus stock is still worth buying after its 1,000% increase since the market crash.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

A market crash usually causes the price of stocks to plummet. In the case of Avacta Group (LSE:AVCT), the opposite has occurred. Listed on the FTSE-AIM for approximately 15 years, AVCT is not a flash in the pan.

The Covid-19 pandemic opened up a vacuum, whereby pharmaceutical companies began to develop coronavirus-related products. As a result vaccines, testing kits, and track-and-trace applications among other products are being created.

Avacta is a small biotech firm with two core proprietary platforms. One of those is called Affimer, which offers an alternative to traditional antibodies and is derived from small human protein. AVCT’s other work is related to cancer therapy drugs and treatment. Due to its size, it often partners up with larger known pharma giants who need AVCT’s proprietary platforms. 

Market crash sensation

As the market crash occurred, investors will have looked to pick up cheaper-than-usual shares in companies they have followed for some time. The opposite of this strategy would have been to look for burgeoning stocks related to the crash and pandemic, and I believe Avacta is one such stock. The height of the market crash is widely considered to be 18 March. On this date, I could buy Avacta shares for 14p per share. As I write, I would be buying at 176p per share. This is a mammoth 1,157% increase.

One of Avacta’s Covid-19-related partnerships is with Cytiva. Avacta has also recently signed a distribution agreement with Medusa Ltd for direct to consumer sales of its Covid-19-related products. Testing results have been positive for AVCT and I believe it is a market crash opportunity.

Half-year results

At the end of September, AVCT released results for the first half of the year. The update was largely positive and mentioned a new international partnership with a South Korean pharma firm for another new project.

Due to new partnerships and projects it is increasing R&D investment. Furthermore, revenues increased over 60% compared to the same period last year. It seems other pharmaceutical companies are seeking out Avacta’s platforms and work. This is definitely a positive sign and it seems the market crash and pandemic have benefitted Avacta.

My verdict

If I had a crystal ball and envisaged Avacta’s rise I would have been a very happy investor right now. I still feel it is a good investment at its current price, albeit with some risk involved. Full-year results posted earlier this year and recent half-year results show me growth is happening.

I believe there are still market crash bargains and opportunities out there. Avacta may not be as much of a bargain as it was in March, but I still feel it has more to offer. I would not be surprised if the share price increased as further progress of Covid-19-related products emerges. I would be tempted to pick up some shares as part of a diverse portfolio. 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Jabran Khan has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

1 of the best UK shares to consider buying in April

Higher gold prices and a falling share price have put this FTSE 250 stock on Stephen Wright's list of UK…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

The market is wrong about this FTSE 250 stock. I’m buying it in April

Stephen Wright thinks investors should look past a 49% decline in earnings per share and consider investing in a FTSE…

Read more »

Black father and two young daughters dancing at home
Investing Articles

1 FTSE 250 stock I own, and 1 I’d love to buy

Our writer explains why she’s eyeing up this FTSE 250 growth phenomenon, and may buy more shares in this property…

Read more »

View of Tower Bridge in Autumn
Investing Articles

The FTSE 100 is closing in on 8,000 points! Here’s what I’m buying before it’s too late!

As the FTSE 100 keeps gaining momentum, this Fool is on the lookout for bargains. Here's one stock he'd willingly…

Read more »

Investing Articles

3 ideas to help investors aim for a million-pound Stocks & Shares ISA

The UK has a growing number of Stocks and Shares ISA millionaires, and this plan may be one of the…

Read more »

Illustration of flames over a black background
Investing Articles

2 red-hot UK growth stocks to consider buying in April

These two growth stocks are performing well, but can they continue to deliver for investors through 2024 and beyond?

Read more »

Charticle

Is JD Sports Fashion one of the FTSE 100’s best value stocks? Here’s what the charts say!

The JD Sports Fashion share price remains a wild ride during the first quarter. Could it be one of the…

Read more »

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »